Neurogenesis therapeutics program
preclinicaldrug program · high · Wed Jan 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop first-in-class therapeutics that increase neurogenesis for neurological disease and improve hippocampal-dependent memory outcomes.
Therapeutic development targeting a novel signaling pathway, with multiple modalities in parallel and a lead approach using exon-skipping antisense oligonucleotides.
Established proof-of-concept for increasing neurogenesis and enhancing hippocampal-dependent memory in a proprietary mouse model; supported by pre-seed financing announced on 2024-01-17.
Proof-of-concept showed increased neurogenesis and enhanced hippocampal-dependent memory in a proprietary mouse model.